300 Participants Needed

Hip Replacement Liners for Osteoarthritis

Recruiting at 9 trial locations
WJ
RB
WJ
LB
JD
MP
Overseen ByMichael P Bolognesi, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Zimmer Biomet
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines the safety and effectiveness of the G7 Acetabular System for individuals needing a hip replacement due to conditions like osteoarthritis or rheumatoid arthritis. It tests different liners inside the hip joint to determine which performs best over the long term. Suitable candidates for this trial have osteoarthritis or similar conditions and are willing to attend follow-up visits. Participants must also understand and agree to the trial's terms. As an unphased study, this trial allows participants to contribute to valuable research that could enhance future hip replacement options.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that these hip replacement liners are safe for osteoarthritis patients?

Research has shown that the G7 Acetabular System is generally safe and effective for hip replacements. One study found that the G7 modular dual mobility cup is a safe choice without specific risks related to the implant. Patients using the G7 system can expect good safety outcomes.

For the liners used with the G7 system, both the Vivacit-E and Longevity liners have demonstrated positive safety records. The Vivacit-E liner, for example, wears down less than traditional materials, potentially leading to fewer problems over time. Studies have confirmed that these materials are as safe and effective as other similar products available.

Overall, evidence suggests that the G7 Acetabular System and its liners are a well-tolerated option for hip replacement surgery.12345

Why are researchers excited about this trial?

The G7 Acetabular System is unique because it uses advanced liner materials like Vivacit-E and Longevity Highly Crosslinked Polyethylene. These materials are designed to improve wear resistance, potentially making hip replacements last longer compared to standard polyethylene liners. Researchers are excited because these liners could reduce the need for future surgeries, offering a more durable solution for patients with osteoarthritis.

What evidence suggests that the G7 Acetabular System is effective for osteoarthritis?

Research has shown that the G7 Acetabular System, which participants in this trial may receive, is safe and effective for hip replacements when used with either Vivacit-E or Longevity liners. One study found this system to be a reliable choice for patients, with no specific problems related to the implant. Vivacit-E liners contain Vitamin E, which helps reduce wear and tear by preventing damage from oxygen exposure. These liners are designed for strength, making them a good option for long-lasting hip replacements. Overall, evidence supports that this system can work well and last a long time for people needing hip joint replacements.12346

Who Is on the Research Team?

HO

Hillary Overholser

Principal Investigator

Zimmer Biomet

Are You a Good Fit for This Trial?

This trial is for adults with full skeletal maturity who need hip replacement due to conditions like osteoarthritis or fractures. Candidates must be able to follow the study protocol and attend follow-up visits. Pregnant individuals, those with bone formation disorders, severe osteoporosis, infections that could affect the implant site, substance abuse issues, or unmanageable neuromuscular diseases cannot participate.

Inclusion Criteria

I am being treated for a joint condition, arthritis, a functional deformity, or certain types of fractures.
Patient must be able and willing to sign the Institutional Review Board or Ethics Committee (IRB/EC) approved informed consent.
Patient must be able and willing to complete the protocol required follow-up visits.
See 1 more

Exclusion Criteria

Patient is a prisoner.
You are currently pregnant.
I have a condition affecting my blood vessels, muscles, or nerves.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Implantation of the G7 Acetabular Shells with Vivacit-E or Longevity HXLPE liners in primary and revision total hip arthroplasty

Surgical procedure

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of implant survival and adverse events

10 years
Annual visits for assessment

Long-term follow-up

Continued monitoring of patient-reported outcomes and quality of life measures

10 years

What Are the Treatments Tested in This Trial?

Interventions

  • G7 Acetabular System
  • Vivacit-E and Longevity (HXLPE) Liners
Trial Overview The study aims to confirm safety and effectiveness of G7 Acetabular Shells used with Vivacit-E and Longevity HXLPE liners in primary and revision total hip replacements. It's designed to track long-term outcomes in patients receiving these specific hip implant components.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: G7 Shell with Vivacit-E and Longevity Highly Crosslinked Polyethylene LinersExperimental Treatment1 Intervention

G7 Acetabular System is already approved in European Union, United States for the following indications:

🇪🇺
Approved in European Union as G7 Acetabular System for:
🇺🇸
Approved in United States as G7 Acetabular System for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Zimmer Biomet

Lead Sponsor

Trials
383
Recruited
67,800+
Dr. Nitin Goyal profile image

Dr. Nitin Goyal

Zimmer Biomet

Chief Medical Officer since 2021

MD from Harvard Medical School

Ivan Tornos profile image

Ivan Tornos

Zimmer Biomet

Chief Executive Officer since 2023

MBA from the University of Miami School of Business, BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business

Published Research Related to This Trial

In a study of 26 young, active patients receiving dual mobility total hip arthroplasty (THA), blood cobalt levels were significantly higher one year post-surgery compared to a control group, indicating potential metal ion release from the modular cobalt alloy components.
Four patients in the dual mobility group had cobalt levels exceeding the normal reference range, highlighting the need for ongoing monitoring of metal ion levels in patients with this type of prosthesis.
Metal Ion Levels in Young, Active Patients Receiving a Modular, Dual Mobility Total Hip Arthroplasty.Nam, D., Salih, R., Brown, KM., et al.[2018]
The use of dual mobility sockets in hip arthroplasty is on the rise, particularly in revision surgeries, to address potential instability issues.
This report highlights three cases of intra-prosthetic dissociation occurring between the outer polyethylene liner and the femoral head following closed reduction of dislocated prostheses, indicating a possible complication associated with dual mobility designs.
Component dissociation after closed reduction of dual mobility sockets - a report of three cases.Stigbrand, H., Ullmark, G.[2017]
The study analyzed 66 explanted liners from dual mobility total hip arthroplasties, revealing that longer implantation times correlated with more homogeneous wear patterns on the convex side of the liners.
Heat color treatment effectively highlighted wear patterns, indicating that optimal convexity mobility may reduce contact stresses and improve the longevity of the implant, while intra-prosthetic dislocations primarily caused internal circular wear without damaging the liner.
Understanding wear in dual mobility total hip replacement: first generation explant wear patterns.Boyer, B., Neri, T., Geringer, J., et al.[2019]

Citations

NCT05587244 | G7 Freedom Constrained Vivacit-E LinersThe main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular ...
G7® Acetabular System - Zimmer BiometThe G7 Acetabular System is specifically designed to simplify implant and instrument delivery for optimized operative efficiency and maximized clinical ...
G7®Acetabular SystemDislocation Risks he G7 Dual Mobility Metal Liners and Active Articulation Hip Bearings are single-use implants, intended for uncemented applications.
Minimum Two-Year Outcomes of the Zimmer G7 Modular ...Conclusions: The Zimmer G7 modular dual mobility cup appears to be a safe and effective option and does not present specific implant-related ...
G7 Acetabular System With Vivacit-E or Longevity Liner ...The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the ...
MAUDE Adverse Event Report: ZIMMER BIOMET, INC. G7 ...It was reported patient has been indicated for revision due to unknown reasons.No revision has been reported to date.Attempts to obtain additional ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security